188 related articles for article (PubMed ID: 22454058)
21. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
[TBL] [Abstract][Full Text] [Related]
22. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
23. Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.
Wee KB; Pramono ZA; Wang JL; MacDorman KF; Lai PS; Yee WC
PLoS One; 2008 Mar; 3(3):e1844. PubMed ID: 18365002
[TBL] [Abstract][Full Text] [Related]
24. Antisense-mediated exon skipping to shift alternative splicing to treat cancer.
Wan J
Methods Mol Biol; 2012; 867():201-8. PubMed ID: 22454063
[TBL] [Abstract][Full Text] [Related]
25. Overview on applications of antisense-mediated exon skipping.
van Roon-Mom WM; Aartsma-Rus A
Methods Mol Biol; 2012; 867():79-96. PubMed ID: 22454056
[TBL] [Abstract][Full Text] [Related]
26. Antisense Oligonucleotide Design and Evaluation of Splice-Modulating Properties Using Cell-Based Assays.
Slijkerman R; Kremer H; van Wijk E
Methods Mol Biol; 2018; 1828():519-530. PubMed ID: 30171565
[TBL] [Abstract][Full Text] [Related]
27. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
28. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
[TBL] [Abstract][Full Text] [Related]
29. Optimizing splice-switching oligomer sequences using 2'-O-methyl phosphorothioate chemistry.
Adkin C; Fletcher S; Wilton SD
Methods Mol Biol; 2012; 867():169-88. PubMed ID: 22454061
[TBL] [Abstract][Full Text] [Related]
30. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
31. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
Garanto A; Collin RWJ
Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
[TBL] [Abstract][Full Text] [Related]
32. The assembly and evaluation of antisense oligonucleotides applied in exon skipping for titin-based mutations in dilated cardiomyopathy.
Hahn JK; Neupane B; Pradhan K; Zhou Q; Testa L; Pelzl L; Maleck C; Gawaz M; Gramlich M
J Mol Cell Cardiol; 2019 Jun; 131():12-19. PubMed ID: 30998980
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the RNase H cleavage kinetics and blood serum stability of the north-conformationally constrained and 2'-alkoxy modified oligonucleotides.
Honcharenko D; Barman J; Varghese OP; Chattopadhyaya J
Biochemistry; 2007 May; 46(19):5635-46. PubMed ID: 17411072
[TBL] [Abstract][Full Text] [Related]
34. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.
Wein N; Avril A; Bartoli M; Beley C; Chaouch S; Laforêt P; Behin A; Butler-Browne G; Mouly V; Krahn M; Garcia L; Lévy N
Hum Mutat; 2010 Feb; 31(2):136-42. PubMed ID: 19953532
[TBL] [Abstract][Full Text] [Related]
35. Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.
Ablinger M; Lettner T; Friedl N; Potocki H; Palmetzhofer T; Koller U; Illmer J; Liemberger B; Hainzl S; Klausegger A; Reisenberger M; Lambert J; Van Gele M; Desmet E; Van Maelsaeke E; Wimmer M; Zauner R; Bauer JW; Wally V
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805154
[TBL] [Abstract][Full Text] [Related]
36. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of VEGF mRNA by 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions.
Morita K; Yamate K; Kurakata S; Abe K; Watanabe K; Koizumi M; Imanishi T
Nucleosides Nucleotides Nucleic Acids; 2006; 25(4-6):503-21. PubMed ID: 16838842
[TBL] [Abstract][Full Text] [Related]
38. Antisense Oligonucleotide-Based Rescue of Complex Intronic Splicing Defects in
Corradi Z; Hitti-Malin RJ; de Rooij LA; Garanto A; Collin RWJ; Cremers FPM
Nucleic Acid Ther; 2024; 34(3):125-133. PubMed ID: 38800942
[TBL] [Abstract][Full Text] [Related]
39. Double sugar and phosphate backbone-constrained nucleotides: synthesis, structure, stability, and their incorporation into oligodeoxynucleotides.
Zhou C; Plashkevych O; Chattopadhyaya J
J Org Chem; 2009 May; 74(9):3248-65. PubMed ID: 19348480
[TBL] [Abstract][Full Text] [Related]
40. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
